DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Azithromycin: a new therapeutical strategy for acne in adolescents.

Author(s): Bardazzi F, Savoia F, Parente G, Tabanelli M, Balestri R, Spadola G, Dika E

Affiliation(s): Department of Specialistic and Experimental Clinical Medicine, Division of Dermatology,University of Bologna, Italy.

Publication date & source: 2007-10-13, Dermatol Online J., 13(4):4.

Publication type: Clinical Trial

AIM: To study the efficacy, safety, and compliance of 500 mg azithromycin thrice weekly for 8 weeks to treat acne vulgaris in adolescents. METHODS: An open-label, non-comparative study was carried out for 8 weeks. Fifty-two teenagers with moderate to severe papulo-pustular acne vulgaris were enrolled. Azithromycin, 500 mg orally thrice weekly for 8 weeks, was prescribed. No topical treatment was permitted. At the baseline visit, patients were scheduled to return at two-weekly intervals for 8 weeks. Efficacy was gauged by the percentage clearance of papulo-pustular acne lesions. All patients were also evaluated at four months post-treatment. RESULTS: A majority of patients (47/52) showed remarkable improvement in the first 4 weeks with a more than 20 percent reduction of their inflammatory papulo-pustular lesions. Maximum clearance was observed in 32 patients at 8 weeks. Slow improvement with eruptions of new lesions was seen in 6 patients. Adverse events, such as heartburn and nausea, were reported by 3 patients. All patients completed the 8-week study period. The beneficial effect was maintained at 4 months after the conclusion of treatment. CONCLUSIONS: Azithromycin, 500 mg thrice weekly for 8 weeks, appears to be a safe and effective treatment for acne vulgaris in adolescents, with excellent patient compliance.

Page last updated: 2008-06-22

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017